The use of tafasitamab-cxix, lenalidomide, rituximab, and acalabrutinib in the first-line setting induced high responses in patients with newly diagnosed diffuse large B-cell lymphoma, with responders deriving benefit from subsequent treatment with cyclophosphamide, doxorubicin, vincristine, and prednisolone.
With 16 cancer drugs on the FDA s drug shortage list, Jason Westin, MD, spoke to the Senate Finance Committee on behalf of the Association for Clinical Oncology.
An overall survival (OS analysis of the phase 3 ZUMA-7 trial demonstrated longer OS in patients treated with axicabtagene ciloleucel (axi-cel) vs the standard of care for early relapsed or refractory (R/R) large B-cell lymphoma (LBCL).